These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 22668202)

  • 1. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
    Marconescu P; Graviss EA; Musher DM
    Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE; Fallon M; Moran JJ; Vanderloo JP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
    Mendes RE; Sader HS; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Davis KP; McDermott LA; Snydman DR; Aldridge BB
    Microbiol Spectr; 2024 Aug; 12(8):e0097624. PubMed ID: 38916355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
    Rolston KVI; Jamal M; Nesher L; Raad I; Rice SA; Rybak MJ; Prince RA
    J Glob Antimicrob Resist; 2019 Jun; 17():16-18. PubMed ID: 30844496
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; MacGowan AP
    J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.